124 related articles for article (PubMed ID: 22773795)
1. Reaping the benefits of recent advances for adults with acute lymphoblastic leukemia.
Brown PA; Alvarnas JC
J Natl Compr Canc Netw; 2012 Jul; 10(7):800-1. PubMed ID: 22773795
[No Abstract] [Full Text] [Related]
2.
Byun JM; Koh Y; Shin DY; Kim I; Yoon SS; Lee JO; Bang SM; Kim KH; Jung SH; Lee WS; Park Y; Jang JH; Han JJ; Yhim HY; Kim DS; Lee YJ; Lee H; Choi YS; Lee S;
Haematologica; 2017 May; 102(5):e187-e190. PubMed ID: 28082339
[No Abstract] [Full Text] [Related]
3. BCR/ABL1 Kinase Domain Mutation Monitoring: Could Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Benefit As Well?
Andolina JR
Acta Haematol; 2015; 134(2):69-70. PubMed ID: 25895547
[No Abstract] [Full Text] [Related]
4. Tyrosine kinase inhibitors in BCR-ABL positive acute lymphoblastic leukemia.
Leoni V; Biondi A
Haematologica; 2015 Mar; 100(3):295-9. PubMed ID: 25740105
[No Abstract] [Full Text] [Related]
5. Expression profiling of adult acute lymphoblastic leukemia identifies a BCR-ABL1-like subgroup characterized by high non-response and relapse rates.
Boer JM; Koenders JE; van der Holt B; Exalto C; Sanders MA; Cornelissen JJ; Valk PJ; den Boer ML; Rijneveld AW
Haematologica; 2015 Jul; 100(7):e261-4. PubMed ID: 25769542
[No Abstract] [Full Text] [Related]
6. Three novel patient-derived BCR/ABL mutants show different sensitivity to second and third generation tyrosine kinase inhibitors.
Redaelli S; Mologni L; Rostagno R; Piazza R; Magistroni V; Ceccon M; Viltadi M; Flynn D; Gambacorti-Passerini C
Am J Hematol; 2012 Nov; 87(11):E125-8. PubMed ID: 23044928
[TBL] [Abstract][Full Text] [Related]
7. T315I mutation exerts a dismal prognosis on adult BCR-ABL1-positive acute lymphoblastic leukemia, and salvage therapy with ponatinib or CAR-T cell and bridging to allogeneic hematopoietic stem cell transplantation can improve clinical outcomes.
Ting S; Mixue X; Lixia Z; Xueying L; Wanzhuo X; Xiujin Y
Ann Hematol; 2020 Apr; 99(4):829-834. PubMed ID: 32107574
[TBL] [Abstract][Full Text] [Related]
8. Clinical impact of low-burden BCR-ABL1 mutations detectable by amplicon deep sequencing in Philadelphia-positive acute lymphoblastic leukemia patients.
Soverini S; De Benedittis C; Papayannidis C; Polakova KM; Venturi C; Russo D; Bresciani P; Iurlo A; Mancini M; Vitale A; Chiaretti S; Foà R; Abruzzese E; Sorà F; Kohlmann A; Haferlach T; Baccarani M; Cavo M; Martinelli G
Leukemia; 2016 Jul; 30(7):1615-9. PubMed ID: 26867670
[No Abstract] [Full Text] [Related]
9. Emerging BCR/ABL1 Mutations Under Treatment with Tyrosine Kinase Inhibitors in Paediatric Acute Lymphoblastic Leukaemia.
Molinos-Quintana A; Aquino V; Montero I; Pérez-de Soto C; García-Lozano R; Pérez-Simón JA; Pérez-Hurtado JM
Acta Haematol; 2015; 134(2):71-5. PubMed ID: 25895602
[TBL] [Abstract][Full Text] [Related]
10. Resistance to dasatinib in Philadelphia-positive leukemia patients and the presence or the selection of mutations at residues 315 and 317 in the BCR-ABL kinase domain.
Soverini S; Colarossi S; Gnani A; Castagnetti F; Rosti G; Bosi C; Paolini S; Rondoni M; Piccaluga PP; Palandri F; Giannoulia P; Marzocchi G; Luatti S; Testoni N; Iacobucci I; Cilloni D; Saglio G; Baccarani M; Martinelli G
Haematologica; 2007 Mar; 92(3):401-4. PubMed ID: 17339191
[TBL] [Abstract][Full Text] [Related]
11. Advances in the management of Ph-positive ALL.
Hoelzer D
Clin Adv Hematol Oncol; 2006 Nov; 4(11):804-5. PubMed ID: 17143248
[No Abstract] [Full Text] [Related]
12. Combining blinatumomab with targeted therapy for BCR-ABL mutant relapsed/refractory acute lymphoblastic leukemia.
Hanif A; Wang ES; Thompson JE; Baron JI; Walsh MD; Griffiths EA
Leuk Lymphoma; 2018 Aug; 59(8):2011-2013. PubMed ID: 29251203
[No Abstract] [Full Text] [Related]
13. As leukemia options grow, drugs jockey to be first-line therapies.
Dolgin E
Nat Med; 2013 Jan; 19(1):7. PubMed ID: 23295994
[No Abstract] [Full Text] [Related]
14. Prevalence and dynamics of bcr-abl kinase domain mutations during imatinib treatment differ in patients with newly diagnosed and recurrent bcr-abl positive acute lymphoblastic leukemia.
Pfeifer H; Lange T; Wystub S; Wassmann B; Maier J; Binckebanck A; Giagounidis A; Stelljes M; Schmalzing M; Dührsen U; Wunderle L; Serve H; Brück P; Schmidt A; Hoelzer D; Ottmann OG
Leukemia; 2012 Jul; 26(7):1475-81. PubMed ID: 22230800
[TBL] [Abstract][Full Text] [Related]
15. T315L: a novel mutation within BCR-ABL kinase domain confers resistance against ponatinib.
Wang D; Pan H; Wang Y
Leuk Lymphoma; 2017 Jul; 58(7):1733-1735. PubMed ID: 27813432
[No Abstract] [Full Text] [Related]
16. Efficacy of tyrosine kinase inhibitors in Ph-like acute lymphoblastic leukemia harboring ABL-class rearrangements.
Tanasi I; Ba I; Sirvent N; Braun T; Cuccuini W; Ballerini P; Duployez N; Tanguy-Schmidt A; Tamburini J; Maury S; Doré E; Himberlin C; Duclos C; Chevallier P; Rousselot P; Bonifacio M; Cavé H; Baruchel A; Dombret H; Soulier J; Landman-Parker J; Boissel N; Clappier E
Blood; 2019 Oct; 134(16):1351-1355. PubMed ID: 31434701
[No Abstract] [Full Text] [Related]
17. Drug resistance and BCR-ABL kinase domain mutations in Philadelphia chromosome-positive acute lymphoblastic leukemia from the imatinib to the second-generation tyrosine kinase inhibitor era: The main changes are in the type of mutations, but not in the frequency of mutation involvement.
Soverini S; De Benedittis C; Papayannidis C; Paolini S; Venturi C; Iacobucci I; Luppi M; Bresciani P; Salvucci M; Russo D; Sica S; Orlandi E; Intermesoli T; Gozzini A; Bonifacio M; Rigolin GM; Pane F; Baccarani M; Cavo M; Martinelli G
Cancer; 2014 Apr; 120(7):1002-9. PubMed ID: 24382642
[TBL] [Abstract][Full Text] [Related]
18. The impacts of BCR-ABL1 mutations in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia who underwent allogeneic hematopoietic cell transplantation.
Tachibana T; Najima Y; Akahoshi Y; Hirabayashi S; Harada K; Doki N; Uchida N; Fukuda T; Sawa M; Ogata M; Takada S; Tanaka M; Matsuhashi Y; Tanaka J; Onizuka M; Ichinohe T; Atsuta Y; Kako S;
Ann Hematol; 2020 Oct; 99(10):2393-2404. PubMed ID: 32803312
[TBL] [Abstract][Full Text] [Related]
19. Drug development: target practice.
Katsnelson A
Nature; 2013 Jun; 498(7455):S8-9. PubMed ID: 23803950
[No Abstract] [Full Text] [Related]
20. Crizotinib acts as ABL1 inhibitor combining ATP-binding with allosteric inhibition and is active against native BCR-ABL1 and its resistance and compound mutants BCR-ABL1
Mian AA; Haberbosch I; Khamaisie H; Agbarya A; Pietsch L; Eshel E; Najib D; Chiriches C; Ottmann OG; Hantschel O; Biondi RM; Ruthardt M; Mahajna J
Ann Hematol; 2021 Aug; 100(8):2023-2029. PubMed ID: 34110462
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
